Preoperative Antibiotics for Carpal Tunnel Release Surgery

October 12, 2021 updated by: Richard C Trevino, MD, WellSpan Health

Endoscopic Carpal Tunnel Release, Infection Incidence, and Prophylactic Antibiotics: Indicated or Kick the Habit?

This is a clinical trial to determine how effective antibiotics administered prior to endoscopic carpal tunnel release surgery are in preventing surgical site infections.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Study participants will be randomized to a prophylactic IV antibiotic treatment arm (Vancomycin or Cefazolin) or a placebo IV saline solution. Subjects will be monitored following surgery for surgical site infections.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
184

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Pennsylvania
      • York, Pennsylvania, United States, 17404
        • WellSpan Surgery and Rehab Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • High probability (>12 points) on the Carpal Tunnel-6 diagnostic aide
  • Recommendation for carpal tunnel release
  • Capable of providing informed consent/LAR to act on subject's behalf

Exclusion Criteria:

  • Patients allergic to both penicillin/cephalosporins and vancomycin
  • Patient immobilized with splint or cast
  • Unwilling unable to provide informed consent
  • Children under the age of 18

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Vancomycin
Drug: Vancomycin
Vancomycin - 1-gram dosing
Placebo Comparator: Saline
Drug: Saline Solution
Placebo
Active Comparator: Cefazolin
Drug: Cefazolin
2-gram dosing for patients <120 kg 3-gram dosing for patients 120 kg or greater

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Number of Participants With Surgical Site Infection
Time Frame: 2 weeks post-operative
Definitive diagnosis of infection of surgical site -wounds determined to be infected will be divided into superficial or deep infections and treated according to the standard of care at WellSpan health.
2 weeks post-operative
Number of Participants With Surgical Site Infection
Time Frame: 6 weeks post-operative
Definitive diagnosis of infection of surgical site -Definitive diagnosis of infection of surgical site -wounds determined to be infected will be divided into superficial or deep infections and treated according to the standard of care at WellSpan health.
6 weeks post-operative

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Number of Participants With Diabetes Diagnosis and Surgical Site Infection
Time Frame: 2 weeks post-operative
Number of patients with surgical site infection that have diabetes
2 weeks post-operative
Number of Participants With Diabetes Diagnosis and Surgical Site Infection
Time Frame: 6 weeks post-operative
Number of patients with surgical site infection that have diabetes
6 weeks post-operative
Number of Participants With Surgical Site Infections That Use Tobacco
Time Frame: 2 weeks post-operative
Number of patients with surgical site infections that use tobacco products
2 weeks post-operative
Number of Participants With Surgical Site Infections That Use Tobacco
Time Frame: 6 weeks post-operative
Number of patients with surgical site infections that use tobacco products
6 weeks post-operative
Number of Participants With Chronic Obstructive Pulmonary Disease Diagnosis and Surgical Site Infection
Time Frame: 2 weeks post-operative
Number of patients with surgical site infections that have chronic obstructive pulmonary disease
2 weeks post-operative
Number of Participants With Chronic Obstructive Pulmonary Disease Diagnosis and Surgical Site Infection
Time Frame: 6 weeks post-operative
Number of patients with surgical site infections that have chronic obstructive pulmonary disease
6 weeks post-operative
Number of Participants With Anemia Diagnosis and Surgical Site Infection
Time Frame: 2 weeks post-operative
Number of patients with surgical site infections that have anemia
2 weeks post-operative
Number of Participants With Anemia Diagnosis and Surgical Site Infection
Time Frame: 6 weeks post-operative
Number of patients with surgical site infections that have anemia
6 weeks post-operative
Number of Participants With Peripheral Artery Disease Diagnosis and Surgical Site Infection
Time Frame: 2 weeks post-operative
Number of patients with surgical site infections that have peripheral artery disease
2 weeks post-operative
Number of Participants With Peripheral Artery Disease Diagnosis and Surgical Site Infection
Time Frame: 6 weeks post-operative
Number of patients with surgical site infections that have peripheral artery disease
6 weeks post-operative
Number of Participants With Surgical Site Infection and a History of Arthroplasty
Time Frame: 2 weeks post-operative
Number of patients with surgical site infections with history of arthroplasty
2 weeks post-operative
Number of Participants With Surgical Site Infection and History of Arthroplasty
Time Frame: 6 weeks post-operative
Number of patients with surgical site infections with history of arthroplasty
6 weeks post-operative
Number of Participants With Valvular Disease Diagnosis and Surgical Site Infection
Time Frame: 2 weeks post-operative
Number of patients with surgical site infections with valvular disease
2 weeks post-operative
Number of Participants With Valvular Disease Diagnosis and Surgical Site Infection
Time Frame: 6 weeks post-operative
Number of patients with surgical site infections with valvular disease
6 weeks post-operative
Number of Participants With Surgical Site Infection That Underwent Single Incision Endoscopic Carpal Tunnel Release
Time Frame: 2 weeks post-operative
Number of patients with surgical site infections with single incision ECTR
2 weeks post-operative
Number of Participants With Surgical Site Infection That Underwent Single Incision Endoscopic Carpal Tunnel Release
Time Frame: 6 weeks post-operative
Number of patients with surgical site infections with single incision ECTR
6 weeks post-operative
Number of Participants With Surgical Site Infection That Underwent Double Incision Endoscopic Carpal Tunnel Release
Time Frame: 2 weeks post-operative
Number of patients with surgical site infections with double incision ECTR
2 weeks post-operative
Number of Participants With Surgical Site Infection That Underwent Double Incision Endoscopic Carpal Tunnel Release
Time Frame: 6 weeks post-operative
Number of patients with surgical site infections with double incision ECTR
6 weeks post-operative
Time From Last Cortisone Injection
Time Frame: 2 weeks post-operative
For patients sustaining surgical site infection, the time from their last cortisone injection
2 weeks post-operative
Time From Last Cortisone Injection
Time Frame: 6 weeks post-operative
For patients sustaining surgical site infection, the time from their last cortisone injection
6 weeks post-operative
Acuity of Carpal Tunnel Syndrome
Time Frame: 2 weeks post-operative
For patients sustaining surgical site infection, the acuity of their carpal tunnel syndrome
2 weeks post-operative
Acuity of Carpal Tunnel Syndrome
Time Frame: 6 weeks post-operative
For patients sustaining surgical site infection, the acuity of their carpal tunnel syndrome
6 weeks post-operative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
WellSpan Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 17, 2018

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 14, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 14, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 6, 2018

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 12, 2018

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 14, 2018

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 10, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 12, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Prophylactic Antibiotics: ESCR

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings